For the Inventor, By the Inventor

Enter assignee name

Planegg, Germany

Ethris Gmbh

USPTO Granted Patents = 23

CIPO Patents = 5

EPO Patents = 20

Trademarks = 1

Forward Citations = 127

Loading Chart...

Loading Chart...

20 inventors (with patents filed for the assignee):

Carsten Rudolph (22 out of 23 patents)

Christian Plank (12 out of 13 patents)

Manish Kumar Aneja (6 out of 6 patents)

4. Braydon Charles Guild (5 out of 58 patents)

5. Frank DeRosa (5 out of 144 patents)

6. Michael W Heartlein (5 out of 175 patents)

7. Johannes-Peter Geiger (4 out of 4 patents)

8. Ludwig Weiss (3 out of 4 patents)

9. Lianne Smith (3 out of 12 patents)

10. Johannes Geiger (3 out of 3 patents)

11. Christian Dohmen (3 out of 3 patents)

12. Mehrije Ferizi (2 out of 2 patents)

13. Rebekka Kubisch-Dohmen (2 out of 2 patents)

14. Günther Hasenpusch (2 out of 2 patents)

15. Marino Schuhmacher (1 out of 1 patent)

23 patents: Sort by Forward Citations

1. 12465568 - Cryoprotective agents for particulate formulations (2025-11-11),

2. 12263229 - Induction of osteogenesis by delivering BMP encoding RNA (2025-04-01),

3. 12064484 - Compositions for introducing RNA into cells (2024-08-20),

4. 11981910 - Minimal UTR sequences (2024-05-14),

5. 11510937 - CFTR MRNA compositions and related methods and uses (2022-11-29),

6. 11479768 - ATP-binding cassette family coding polyribonucleotides and formulations thereof (2022-10-25),

7. 11352638 - Minimal UTR sequences (2022-06-07),

8. 11136585 - UTRs increasing the translation efficiency of RNA molecules (2021-10-05),

9. 11104887 - Ornithine transcarbamylase coding polyribonucleotides and formulations thereof (2021-08-31),

10. 11090264 - Pulmonary delivery of mRNA to non-lung target cells (2021-08-17),

11. 11065346 - RNA for use in the treatment of ligament or tendon lesions (2021-07-20),

12. 11020487 - Compositions for introducing nucelic acid into cells (2021-06-01),

13. 10927383 - Cas9 mRNAs (2021-02-23),

14. 10745698 - RNA with a combination of unmodified and modified nucleotides for protein expression (2020-08-18),

15. 10583195 - Conjugate with target-finding ligand and use thereof (2020-03-10),

Ethris GmbH is a biotechnology company focused on the discovery, development, and commercialization of RNA-based therapeutics. Applying their proprietary messenger RNA platform, they aim to tackle diseases with high unmet medical need, including rare genetic disorders and respiratory diseases. With their expertise in RNA engineering, delivery systems, and manufacturing processes, Ethris is dedicated to providing innovative treatments that can improve the lives of patients.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 16 2025

23 Patents

#2 in Planegg

#1,996 in Germany

#26,801 in the World

Planegg, Germany

Ethris Gmbh

Forward Citations = 127

20 inventors:

Carsten Rudolph (22 out of 23 patents)

Christian Plank (12 out of 13 patents)

Manish Kumar Aneja (6 out of 6 patents)

4. Braydon Charles Guild (5 out of 58 patents)

5. Frank DeRosa (5 out of 144 patents)

Please report any incorrect information to support@idiyas.com

Loading…